BNR Earnings Date: Nov 17, 2026 (Estimated) — Burning Rock Biotech Limited
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is BNR's next earnings date?
Burning Rock Biotech Limited (BNR) is expected to report earnings on Tuesday, November 17, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.29 on revenue of $19.2M.
How did BNR do in its last earnings report?
In its most recent report on Sep 10, 2026 (Q2 2026), Burning Rock Biotech Limited posted EPS of -$0.20 versus the -$2.29 estimate, a beat of 91.3%. Revenue was $19.9M against a $19.2M estimate. The stock's 1-day post-earnings move was -3.1%.
How much does BNR stock move after earnings?
BNR beat EPS estimates in 1 of its last 1 reported quarter. Over the last 8 reports the stock moved an average of 6.0% (up or down) in the day after earnings.
About Burning Rock Biotech Limited
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | Q2 2026 | -2.29 | -0.20 | +91.26% | $19.9M | ✅ Beat | -3.09% | +4.42% | +26.77% |
| 2026-06-09 | Q1 2026 | — | -0.20 | — | $15.6M | — | -9.81% | -3.42% | +29.00% |
| 2026-03-12 | Q4 2025 | — | -0.20 | — | $18.1M | — | -2.60% | -20.63% | -32.46% |
| 2025-11-20 | Q3 2025 | — | -0.20 | — | $18.5M | — | -3.10% | +33.13% | +35.37% |
| 2025-09-08 | Q2 2025 | — | -0.10 | — | $20.7M | — | +9.16% | +0.00% | +14.46% |
| 2025-03-25 | Q4 2024 | — | -1.10 | — | $17.3M | — | -12.36% | -18.18% | -46.55% |
| 2024-12-03 | Q3 2024 | — | -0.50 | — | $18.3M | — | +0.99% | +16.22% | +22.35% |
| 2024-08-22 | Q2 2024 | — | -1.40 | — | $18.6M | — | -6.76% | -13.52% | -44.37% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY22 · $296.9M total
| Segment | Share | Revenue | YoY | Q4 FY22 |
|---|---|---|---|---|
| Service | 69.4% | $206.0M | — | $206.0M |
| Product | 30.6% | $90.9M | — | $90.9M |
By region
FY2024 · $515.8M total · annual
| Segment | Share | Revenue | YoY | FY2023 | FY2024 |
|---|---|---|---|---|---|
| CHINA | 98.9% | $510.2M | -4.6% | $534.9M | $510.2M |
| UNITED STATES | 1.1% | $5.6M | +122.6% | $2.5M | $5.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.